URGN - UroGen Pharma Ltd.
NEXT EARNINGS:
Mar 9, 2026
(in 12 days)
EPS Est: $-0.66
|
Rev Est: $39.9M
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$35.60
DETAILS
HIGH:
$60.00
LOW:
$16.00
MEDIAN:
$31.00
CONSENSUS:
$35.60
UPSIDE:
71.57%
Market Cap:
971.28M
Volume:
378,615
Avg Volume:
774,441
52 Week Range:
3.42-30
Sector:
Healthcare
Industry:
Biotechnology
Beta:
1.36
Last Dividend:
$N/A
Exchange:
NASDAQ
Country:
US
Employees:
234
IPO Date:
2017-05-04
EPS (TTM):
-2.96
P/E Ratio:
-3.60
Revenue (TTM):
90.40M
Total Assets:
285.71M
Total Debt:
123.39M
Cash & Equiv:
171.99M
Rev Growth (5Y):
449.4%
EPS Growth (5Y):
N/A
FCF Growth (5Y):
N/A
ROCE:
-39.9%
Debt/Equity:
-14.02
Earnings History
| Date | EPS Actual | EPS Est | EPS Surprise | Rev Actual | Rev Est | Rev Surprise |
|---|---|---|---|---|---|---|
| 2025-11-06 | $-0.69 | $-0.72 | +4.2% | $27.5M | $40.1M | -31.5% |
| 2025-08-07 | $-1.05 | $-0.82 | -28.0% | $24.2M | $33.6M | -27.9% |
| 2025-05-12 | $-0.92 | $-0.83 | -10.8% | $20.3M | $23.3M | -12.9% |
| 2025-03-10 | $-0.80 | $-0.69 | -15.9% | $24.6M | $23.3M | +5.2% |
| 2024-11-06 | $-0.55 | $-0.84 | +34.5% | $25.2M | $26.1M | -3.6% |
| 2024-08-13 | $-0.91 | $-0.82 | -11.0% | $21.8M | $24.0M | -8.8% |
| 2024-05-13 | $-0.97 | $-0.93 | -4.3% | $18.8M | $21.4M | -12.2% |
| 2024-03-14 | $-0.72 | $-0.67 | -7.5% | $23.5M | $22.6M | +4.3% |
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 90.40M | 82.71M | 64.36M | 48.04M | 11.80M | 18,000 | 1.13M | 8.16M | 17.53M | 0 | 0 | 0 |
| Net Income | (126.87M) | (102.24M) | (109.78M) | (110.82M) | (128.48M) | (105.15M) | (75.66M) | (20.00M) | (1.94M) | (12.69M) | (4.56M) | (3.31M) |
| EPS | -2.96 | -3.55 | -4.79 | -4.96 | -5.90 | -4.90 | -4.80 | -2.06 | -0.16 | -5.51 | -1.98 | -1.56 |
| Total Assets | 285.71M | 178.31M | 135.62M | 119.75M | 122.00M | 202.39M | 103.56M | 75.55M | 23.06M | 19.39M | 4.36M | 3.23M |
| Total Debt | 123.39M | 99.39M | 99.12M | 398,000 | 1.50M | 2.60M | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash & Equivalents | 171.99M | 95.00M | 55.41M | 44.36M | 52.86M | 49.69M | 101.32M | 37.00M | 21.36M | 17.98M | 3.87M | 3.04M |
| Operating Cash Flow | (96.77M) | (76.38M) | (87.56M) | (84.89M) | (105.89M) | (71.02M) | (37.33M) | (9.57M) | 4.19M | (7.17M) | (4.12M) | (2.56M) |
| Free Cash Flow | (97.06M) | (76.57M) | (87.81M) | (85.64M) | (107.10M) | (71.34M) | (37.89M) | (9.84M) | 3.49M | (7.48M) | (4.14M) | (2.61M) |
| FCF per Share | -2.26 | -2.66 | -3.85 | -3.83 | -4.92 | -3.48 | -2.41 | -1.01 | 0.29 | -3.25 | -1.80 | -1.23 |
| Book Value | (8.80M) | (65.21M) | (89.36M) | 8.41M | 96.36M | 180.30M | 90.09M | 68.52M | 16.31M | 17.15M | 3.47M | 2.74M |
| Cash & ST Investments | 236.69M | 136.97M | 99.96M | 89.14M | 102.02M | 147.08M | 101.32M | 73.00M | 21.36M | 17.98M | 3.87M | 3.04M |
| ROC Equity | N/A | N/A | N/A | -13.17 | -1.33 | -0.58 | -0.84 | -0.29 | -0.12 | -0.74 | -1.31 | -1.21 |